Centre Hospitalier Universitaire de Saint Etienne
chu-st-etienne.frTotal trials
583
Active
124
Phase 3
25
Total enrollment
872,067
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 33 of 33 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adalimumab | — | — | — | — | — | 2 | |
| Vedolizumab | — | — | — | — | — | 2 | |
| Biological tests | — | — | — | — | — | 1 | |
| Clinical tapering strategy | — | — | — | — | — | 1 | |
| Step Wedge trial | — | — | — | — | — | 1 | |
| Flu Vaccine | — | — | — | — | — | 1 | |
| Biological samples | — | — | — | — | — | 1 | |
| Early intervention | — | — | — | — | — | 1 | |
| Delayed intervention | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Premedications | — | — | — | — | — | 1 | |
| Full-dose anticoagulant therapy | — | — | — | — | — | 1 | |
| Antiplatelet therapy | — | — | — | — | — | 1 | |
| Hydroxychloroquine | — | — | — | — | 3 | ||
| CAR-T cells | — | — | — | — | — | 1 | |
| BCMA bispecific | — | — | — | — | — | 1 | |
| Mupirocin | — | — | — | — | — | 1 | |
| blood samples after Single dose part | — | — | — | — | — | 1 | |
| Blood sample | — | — | — | 13 | |||
| Blood samples | — | — | — | — | 5 | ||
| Apixaban | — | — | — | — | 2 | ||
| Urinary sample | — | — | — | — | — | 2 | |
| Blood samples for PK | — | — | — | — | — | 1 | |
| Blood collection before antiplatelet treatment | — | — | — | — | — | 1 | |
| Blood collection after antiplatelet treatment | — | — | — | — | — | 1 | |
| Genotyping | — | — | — | — | — | 1 | |
| Blood sampling for patients only | — | — | — | — | — | 1 | |
| Thrombin Generation Assay | — | — | — | — | — | 1 | |
| ceftazidime | — | — | — | — | — | 1 | |
| plasma ceftazidime dosage | — | — | — | — | — | 1 | |
| Venous sampling | — | — | — | — | — | 1 | |
| Antibiotic treatment | — | — | — | — | — | 1 | |
| Intracellular reservoir test | — | — | — | — | — | 1 |
Next readouts
- 2025-01-01
- 2025-03
- 2025-03-04
- 2025-11
- 2025-12-19
- 2026-01
- 2026-01-01
- 2026-06
- 2026-06-01
- 2026-08-01
Top conditions
- Healthy23
- Aging11
- Healthy Volunteers11
- Cancer11
- Stroke8
- Neuropathic Pain8
- Schizophrenia8
- Alzheimer Disease7
Frequently asked questions about Centre Hospitalier Universitaire de Saint Etienne
- How many clinical trials does Centre Hospitalier Universitaire de Saint Etienne have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire de Saint Etienne is listed as the lead sponsor on 583 clinical trials in ClinicalTrials.gov, 124 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire de Saint Etienne's trials are in Phase 3?
- 25 of Centre Hospitalier Universitaire de Saint Etienne's trials are in Phase 3, spread across 33 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire de Saint Etienne focus on?
- Centre Hospitalier Universitaire de Saint Etienne's most-studied conditions on ClinicalTrials.gov are Healthy, Aging, Healthy Volunteers, Cancer, Stroke.
- When are Centre Hospitalier Universitaire de Saint Etienne's next clinical trial readouts?
- Centre Hospitalier Universitaire de Saint Etienne has 10 upcoming primary-completion readouts tracked here; the soonest is “Longitudinal Evolution of Biomarkers of Dysautonomia and Inflammation During Sepsis in Children”, expected around 2025-01-01.